Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia

Brain Research

Volumn 1181, Issue 1, 2007, Pages 10-20

  Kalange, Annasaheb S ^a   Kokare, Dadasaheb M ^a   Singru, Praful S ^b   Upadhya, Manoj A ^a   Chopde, Chandrabhan T ^a   Subhedar, Nishikant K ^a  

^a RTM NAGPUR UNIVERSITY   (India)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Chronic icv infusion; Melanocortin 4 receptor; Morphine; Tail flick test; Tolerance; Withdrawal hyperalgesia

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA INTERMEDIN[4 (N LEUCINE),7 DEXTRO PHENYLALANINE]; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 [3 (2 NAPHTHYL) DEXTRO ALANINE] 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MORPHINE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; HYPERALGESIA; MALE; MORPHINE TOLERANCE; NONHUMAN; OSMOTIC MINIPUMP; PAIN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; DRUG TOLERANCE; HYPERALGESIA; INJECTIONS, INTRAVENTRICULAR; MALE; MORPHINE; NEUROPEPTIDES; PAIN; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELANOCORTIN, TYPE 4; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 35948948698     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.08.054     Document Type: Article

References (78)

1. Abdel-Malek Z.A. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell. Mol. Life Sci. 58 (2001) 434-441
2. Aceto M.D., Dewey W.L., Portoghese P.S., and Takemori A.E. Effects of beta-funaltrexamine (beta-FNA) on morphine dependence in rats and monkeys. Eur. J. Pharmacol. 123 (1986) 387-393
3. Adan R.A., and Gispen W.H. Melanocortins and the brain: from effects via receptors to drug targets. Eur. J. Pharmacol. 405 (2000) 13-24
4. Adan R.A.H., Cone R.D., Burbach J.P.H., and Gispen W.H. Differential effects of melanocortin peptides on neural melanocortin receptors. Mol. Pharmacol. 46 (1994) 1182-1190
5. Alvaro J.D., Tatro J.B., and Duman R.S. Melanocortins and opiate addiction. Life Sci. 61 (1997) 1-9
6. Argiolas A., Melis M.R., Murgia S., and Schioth H.B. ACTH- and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res. Bull. 51 (2000) 425-431
7. Besse D., Lombard M.C., Zajac J.M., Roques B.P., and Besson J.M. Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521 (1990) 15-22
8. Chaki S., Hirota S., Funakoshi T., Suzuki Y., Suetake S., Okubo T., Ishii T., Nakazato A., and Okuyama S. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-m ethoxynapthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J. Pharmacol. Exp. Ther. 304 (2003) 818-826
9. Chaki S., Ogawa S., Toda Y., Funakoshi T., and Okuyama S. Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents. Eur. J. Pharmacol. 474 (2003) 95-101
10. Chaki S., Oshida Y., Ogawa S., Funakoshi T., Shimazaki T., Okubo T., Nakazato A., and Okuyama S. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol. Biochem. Behav. 82 (2005) 621-626
11. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., Rosenblum C.I., Vongs A., Feng Y., Cao L., Metzger J.M., Strack A.M., Camacho R.E., Mellin T.N., Nunes C.N., Min W., Fisher J., Gopal-Truter S., MacIntyre D.E., Chen H.Y., and Van der Ploeg L.H. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26 (2000) 97-102
12. Contreras P.C., and Takemori A.E. Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone. J. Pharmacol. Exp. Ther. 229 (1984) 21-26
13. Delander G.E., and Takemori A.E. Spinal antagonism of tolerance and dependence induced by systemically administered morphine. Eur. J. Pharmacol. 94 (1983) 35-42
14. DeLander G.E., Portoghese P.S., and Takemori A.E. Role of spinal mu opioid receptors in the development of morphine tolerance and dependence. J. Pharmacol. Exp. Ther. 231 (1984) 91-96
15. Demiot C., Tartas M., Fromy B., Abraham P., Saumet J.L., and Sigaudo-Roussel D. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes 55 (2006) 1478-1483
16. Eipper B.A., and Mains R.E. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. Endocr. Rev. 1 (1980) 1-27
17. Ercil N.E., Galici R., and Kestorson R.A. HS014, a selective melanocortin-4 (MC-4) receptor antagonist, modulates the behavioral effects of morphine in mice. Psychopharmacology 180 (2005) 279-285
18. Fan W., Boston B.A., Kestorson R.A., Hruby V.J., and Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385 (1997) 165-168
19. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S.J., Delvalle J., and Yamada T. Molecular cloning, expression and gene localization of a fourth melanocortin receptor. J. Biol. Chem. 268 (1993) 15174-15179
20. Gilron I., Biederman J., Jhamandas K., and Hong M. Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests. Anesthesiology 98 (2003) 1288-1292
21. Goyal S.N., Kokare D.M., Chopde C.T., and Subhedar N.K. Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats. Pharmacol. Biochem. Behav. 85 (2006) 369-377
22. Hadley M.E., and Haskell-Luevano C. The proopiomelanocortin system. Ann. N.Y. Acad. Sci. 885 (1999) 1-21
23. Hansen C., Gilron I., and Hong M. The effects of intrathecal gabapentin on spinal morphine tolerance in the rat tail-flick and paw pressure tests. Anesth. Analg. 99 (2004) 1180-1184
24. Herman B.H., Vocci F., and Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology 13 (1995) 269-293
25. Hillebrand J.J., Kas M.J., and Adan R.A. To eat or not to eat; regulation by the melanocortin system. Physiol. Behav. 89 (2006) 97-102
26. Houshyar H., Galigniana M.D., Pratt W.B., and Woods J.H. Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: possible mechanisms involved in facilitated and attenuated stress responses. J. Neuroendocrinol. 13 (2001) 875-886
27. Jacobowitz D.M., and O'Donohue T.L. alpha-Melanocyte stimulating hormone: immunohistochemical identification and mapping in neurons of rat brain. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 6300-6304
28. Kamei J., Zushida K., Ohsawa M., and Nagase H. The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice. Eur. J. Pharmacol. 391 (2000) 91-96
29. Kastin A.J., Schally A.V., Viosca S., and Miller III M.C. MSH activity in plasma and pituitaries of rats after various treatments. Endocrinology 84 (1969) 20-27
30. Kieffer B.L. Opioid receptors: from genes to mice. J. Pain 1 (2000) 45-50
31. Kim S.Y., Chudapongse N., Lee S.M., Levin M.C., Oh J.T., Park H.J., and Ho I.K. Proteomic analysis of phosphotyrosyl proteins in morphine-dependent rat brains. Mol. Brain Res. 133 (2005) 58-70
32. Kokare D.M., Dandekar M.P., Chopde C.T., and Subhedar N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Res. 1043 (2005) 107-114
33. Kokare D.M., Patole A.M., Carta A., Chopde C.T., and Subhedar N.K. GABAA receptors mediate orexin-A induced stimulation of food intake. Neuropharmacology 50 (2006) 16-24
34. Kokare D.M., Chopde C.T., and Subhedar N.K. Participation of α-melanocyte stimulating hormone in ethanol-induced anxiolysis and withdrawal anxiety in rats. Neuropharmacology 51 (2006) 536-545
35. Lightman S.L., and Young III W.S. Corticotrophin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat. J. Physiol. 403 (1988) 511-523
36. Lin J.A., Lee M.S., Wu C.T., Yeh C.C., Lin S.L., Wen Z.H., and Wong C.S. Attenuation of morphine tolerance by intrathecal gabapentin is associated with suppression of morphine-evoked excitatory amino acid release in the rat spinal cord. Brain Res. 1054 (2005) 167-173
37. Lopez-Fando A., Rodriguez-Munoz M., Sanchez-Blazquez P., and Garzon J. Expression of neural RGS-R7 and Gbeta5 proteins in response to acute and chronic morphine. Neuropsychopharmacology 30 (2005) 99-110
38. Lu L., Liu D., Ceng X., and Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur. J. Neurosci. 12 (2000) 4398-4404
39. Lu X.Y., Barsh G.S., Akil H., and Watson S.J. Interaction between α-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J. Neurosci. 23 (2003) 7863-7872
40. Lu L., Chen H., Su W., Ge X., Yue W., Su F., and Ma L. Role of withdrawal in reinstatement of morphine-conditioned place preference. Psychopharmacology 181 (2005) 90-100
41. Ma W., Zheng W.H., Powell K., Jhamandas K., and Quirion R. Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study. Eur. J. Neurosci. 14 (2001) 1091-1104
42. Maj M., Turchan J., Smialowska M., and Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 37 (2003) 105-110
43. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., and Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (1996) 819-823
44. Mayer D.J., Mao J., Holt J., and Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. 96 (1999) 7731-7736
45. Milanes M.V., Laorden M.L., Angel E., Tankosic P., and Burlet A. Effect of naloxone-precipitated morphine withdrawal on CRH and vasopressin mRNA expression in the rat hypothalamic paraventricular nucleus. Neurosci. Lett. 334 (2002) 58-62
46. Milne B., Cervenko F.W., Jhamandas K., and Sutak M. Intrathecal clonidine: analgesia and effect on opiate withdrawal in the rat. Anesthesiology 62 (1985) 34-38
47. Mountjoy K.G., Robbins L.S., Mortrud M.T., and Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science 257 (1992) 1248-1251
48. Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., and Cone R.D. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 8 (1994) 1298-1308
49. Moskowitz A.S., and Goodman R.R. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Res. 360 (1985) 117-129
50. O'Donohue T.L., and Dorsa D.M. The opiomelanotropinergic neuronal and endocrine systems. Peptides 3 (1982) 353-395
51. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, London
52. Przewlocki R., and Przewlocka B. Opioids in chronic pain. Eur. J. Pharmacol. 429 (2001) 79-91
53. Raghavendra V., Rutkowski M.D., and DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 22 (2002) 9980-9989
54. Raghavendra V., Tanga F.Y., and DeLeo J.A. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29 (2004) 327-334
55. Rao T.L., Kokare D.M., Sarkar S., Khisti R.T., Chopde C.T., and Subhedar N. GABAergic agents prevent alpha-melanocyte stimulating hormone induced anxiety and anorexia in rats. Pharmacol. Biochem. Behav. 76 (2003) 417-423
56. Sandman C.A., and Kastin A.J. Intraventricular administration of MSH induces hyperalgesia in rats. Peptides 2 (1981) 231-233
57. Schioth H.B., Mutulis F., Muceniece R., Prusis P., and Wikberg J.E. Discovery of novel melanocortin 4 receptor selective MSH analogues. Br. J. Pharmacol. 124 (1998) 75-82
58. Schioth H.B., Muceniece R., Mutulis F., Bouifrouri A.A., Mutule I., and Wikberg J.E. Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119. Neuropeptides 33 (1999) 191-196
59. Schwartz M.W., and Wisse B.E. Role of melanocortins in control of obesity. Nat. Genet. 26 (2000) 8-9
60. Shimazaki T., and Chaki S. Anxiolytic-like effect of a selective and non-peptidergic melanocortin 4 receptor antagonist, MCL0129, in a social interaction test. Pharmacol. Biochem. Behav. 80 (2005) 395-400
61. Singru P.S., Sanchez E., Fekete C., and Lechan R.M. Importance of melanocortin signaling in refeeding-induced neuronal activation and satiety. Endocrinology 148 (2007) 638-646
62. Sora I. Opioid receptor knockout mice. Nihon Shinkei Seishin Yakurigaku Zasshi 19 (1999) 239-249
63. Starowicz K., Przewlocki R., Gispen W.H., and Przewlocka B. Modulation of melanocortin-induced changes in spinal nociception by mu-opioid receptor agonist and antagonist in neuropathic rats. NeuroReport 13 (2002) 2447-2452
64. Starowicz K., Sieja A., Bilecki W., Obara I., and Przewlocka B. The effect of morphine on MC4 and CRF receptor mRNAs in the rat amygdala and attenuation of tolerance after their blockade. Brain Res. 990 (2003) 113-119
65. Starowicz K., Obara I., Przewlocki R., and Przewlocka B. Inhibition of morphine tolerance by spinal melanocortin receptor blockade. Pain 117 (2005) 401-411
66. Stinus L., Cador M., Zorrilla E.P., and Koob G.F. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30 (2005) 90-98
67. Tallarida R.J., Kimmel H.L., and Holtzman S.G. Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine. Psychopharmacology 133 (1997) 378-382
68. Tatro J.B., and Entwistle M.L. Heterogeneity of brain melanocortin receptors suggested by differential ligand binding in situ. Brain Res. 635 (1994) 148-158
69. Tsou K., Khachaturian H., Akil H., and Watson S.J. Immunocytochemical localization of pro-opiomelanocortin-derived peptides in the adult rat spinal cord. Brain Res. 378 (1986) 28-35
70. Van Wimersma Greidanus T.B., Thody T.J., Verspaget H., de Rotte G.A., Goedemans H.J., Croiset G., and Ree J.M. Effects of morphine and beta-endorphin on basal and elevated plasma levels of alpha-MSH and vasopressin. Life Sci. 24 (1979) 579-585
71. Vecsernyes M., Biro E., Gardi J., Julesz J., and Telegdy G. Involvement of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral effects to alpha-melanocyte-stimulating hormone. Endocr. Res. 26 (2000) 347-356
72. Von Frijtag J.C., Croiset G., Gispen W.H., Adan R.A., and Wiegant V.M. The role of central melanocortin receptors in the activation of the hypothalamus-pituitary-adrenal axis and the induction of excessive grooming. Br. J. Pharmacol. 123 (1998) 1503-1508
73. Vrinten D.H., Gispen W.H., Groen G.J., and Adan R.A. Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. J. Neurosci. 20 (2000) 8131-8137
74. Vrinten D.H., Gispen W.H., Kalkman C.J., and Adan R.A. Interaction between the spinal melanocortin and opioid systems in a rat model of neuropathic pain. Anesthesiology 99 (2003) 449-454
75. Zhou Y., Spangler R., Maggos C.E., Wang X.M., Han J.S., Ho A., and Kreek M.J. Hypothalamic-pituitary-adrenal activity and pro-opiomelanocortin mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J. Endocrinol. 163 (1999) 261-267
76. Zhu H., Ho I.K., Kramer R.E., Baker R.C., and Rockhold R.W. Methyl parathion masks withdrawal from physical dependence on morphine. Int. J. Mol. Sci. 3 (2002) 1073-1081
77. Zimanyi I.A., and Pelleymounter M.A. The role of melanocortin peptides and receptors in regulation of energy balance. Curr. Pharm. Des. 9 (2003) 627-641
78. Zvejniece L., Muceniece R., Krigere L., Dambrova M., and Klusa V.Z. The differential influences of melanocortins on nociception in the formalin and tail flick tests. Pharmacol. Biochem. Behav. 85 (2006) 287-291